251 related articles for article (PubMed ID: 22646163)
1. Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance.
Grancha S; Ortiz AM; Marañón C; Hampel K; Moret A; Zimmermann B; Jorquera JI; Aznar JA
Haemophilia; 2012 Nov; 18(6):982-9. PubMed ID: 22646163
[TBL] [Abstract][Full Text] [Related]
2. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
Mannucci PM; Shi Q; Bonanad S; Klamroth R
Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
[TBL] [Abstract][Full Text] [Related]
3. Plasma-derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study.
Bravo MI; Pérez A; Raventós A; Grancha S; Jorquera JI; Butta NV; Álvarez-Román MT; Costa M; Willis T; Jiménez-Yuste V
Haemophilia; 2022 Sep; 28(5):737-744. PubMed ID: 35654086
[TBL] [Abstract][Full Text] [Related]
4. Allergic reaction in a cohort of haemophilia A patients using plasma-derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII.
Montalvão SA; Tucunduva AC; Siqueira LH; Sambo AL; Medina SS; Ozelo MC
Haemophilia; 2015 Jul; 21(4):e281-5. PubMed ID: 25929310
[TBL] [Abstract][Full Text] [Related]
5. Understanding FVIII/VWF complex--report from a symposium of XXIX WFH meeting 2010.
Gringeri A; Ofosu FA; Grancha S; Oldenburg J; Ewing NP; Federici AB
Haemophilia; 2012 May; 18(3):469-75. PubMed ID: 21943193
[TBL] [Abstract][Full Text] [Related]
6. Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products.
Jankowski W; Park Y; McGill J; Maraskovsky E; Hofmann M; Diego VP; Luu BW; Howard TE; Kellerman R; Key NS; Sauna ZE
Blood Adv; 2019 May; 3(9):1429-1440. PubMed ID: 31053570
[TBL] [Abstract][Full Text] [Related]
7. Purification of recombinant human B-domain-deleted factor VIII using anti-factor VIII monoclonal antibody selected by the surface plasmon resonance biosensor.
Oh HK; Lee JM; Byun TH; Park SY; Kim YH
Biotechnol Prog; 2001; 17(6):1119-27. PubMed ID: 11735450
[TBL] [Abstract][Full Text] [Related]
8. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes.
Gilles JG; Lavend'homme R; Peerlinck K; Jacquemin MG; Hoylaerts M; Jorieux S; Mazurier C; Vermylen J; Saint-Remy JM
Thromb Haemost; 1999 Jul; 82(1):40-5. PubMed ID: 10456452
[TBL] [Abstract][Full Text] [Related]
9. Management of bleeding disorders: basic science.
Ofosu FA; Santagostino E; Grancha S; Marco P
Haemophilia; 2012 May; 18 Suppl 2():8-14. PubMed ID: 22530574
[TBL] [Abstract][Full Text] [Related]
10. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
Neufeld EJ; Sidonio RF; O'Day K; Runken MC; Meyer K; Spears J
J Med Econ; 2018 Aug; 21(8):762-769. PubMed ID: 29681200
[TBL] [Abstract][Full Text] [Related]
11. Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors.
Bravo MI; Da Rocha-Souto B; Grancha S; Jorquera JI
Haemophilia; 2014 Nov; 20(6):905-11. PubMed ID: 25156825
[TBL] [Abstract][Full Text] [Related]
12. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.
Qadura M; Waters B; Burnett E; Chegeni R; Bradshaw S; Hough C; Othman M; Lillicrap D
Blood; 2009 Jul; 114(4):871-80. PubMed ID: 19411636
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
Delignat S; Dasgupta S; André S; Navarrete AM; Kaveri SV; Bayry J; André MH; Chtourou S; Tellier Z; Lacroix-Desmazes S
Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
[TBL] [Abstract][Full Text] [Related]
14. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.
Seth Chhabra E; Liu T; Kulman J; Patarroyo-White S; Yang B; Lu Q; Drager D; Moore N; Liu J; Holthaus AM; Sommer JM; Ismail A; Rabinovich D; Liu Z; van der Flier A; Goodman A; Furcht C; Tie M; Carlage T; Mauldin R; Dobrowsky TM; Liu Z; Mercury O; Zhu L; Mei B; Schellenberger V; Jiang H; Pierce GF; Salas J; Peters R
Blood; 2020 Apr; 135(17):1484-1496. PubMed ID: 32078672
[TBL] [Abstract][Full Text] [Related]
15. Impact of capacity-limited binding on recombinant factor VIII and von Willebrand factor pharmacokinetics in hemophilia A rats.
Vargas Christensen I; Loftager M; Rode F; Mørck Nielsen H; Kreilgaard M; Larsen MS
J Thromb Haemost; 2019 Jun; 17(6):964-974. PubMed ID: 30924607
[TBL] [Abstract][Full Text] [Related]
16. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
17. High-affinity von Willebrand factor binding does not affect the anatomical or hepatocellular distribution of factor VIII in rats.
Øie CI; Roepstorff K; Behrens C; Bøggild Kristensen J; Karpf DM; Bolt G; Gudme CN; Kjalke M; Smedsrød B; Appa RS
J Thromb Haemost; 2016 Sep; 14(9):1803-13. PubMed ID: 27378673
[TBL] [Abstract][Full Text] [Related]
18. Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.
Veyradier A; Caron C; Ternisien C; Wolf M; Trossaert M; Fressinaud E; Goudemand J
Haemophilia; 2011 Nov; 17(6):944-51. PubMed ID: 21371195
[TBL] [Abstract][Full Text] [Related]
19. More than a decade of international experience with a pdFVIII/VWF concentrate in immune tolerance.
Santagostino E
Haemophilia; 2013 Jan; 19 Suppl 1():8-11. PubMed ID: 23278994
[TBL] [Abstract][Full Text] [Related]
20. Development and applications of surface plasmon resonance-based von Willebrand factor-collagen binding assay.
Saenko E; Kannicht C; Loster K; Sarafanov A; Khrenov A; Kouiavskaia D; Shima M; Ananyeva N; Schwinn H; Gruber G; Josic D
Anal Biochem; 2002 Mar; 302(2):252-62. PubMed ID: 11878805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
